Premium
Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination
Author(s) -
Allen Christopher Martin,
Ramsamy Shelby,
Tarr Alexander William,
Tighe Patrick Jason,
Irving William Lucien,
Tanasescu Radu,
Evans Jonathan Rhys
Publication year - 2021
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.26144
Subject(s) - guillain barre syndrome , covid-19 , vaccination , virology , medicine , immunology , outbreak , disease , infectious disease (medical specialty)
Although SARS‐CoV‐2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford–AstraZeneca SARS‐CoV‐2 vaccine. This rare neurological syndrome has previously been reported in association with SARS‐CoV‐2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS‐CoV‐2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021;90:315–318